secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001193125-21-228150
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q2 net loss $86.2M, cash $1.7B; CMO retirement, mitapivat NDA submitted
-----------------------------------------------------------------------------

- Net loss $86.2M vs $90.5M; cash, cash equivalents and marketable securities $1.7B.
- R&D expenses $62.0M (up from $54.1M) for start-up costs of Phase 3 trials and regulatory filings.
- Completed NDA in U.S. and MAA in EU for mitapivat in adults with PK deficiency.
- Chris Bowden to retire as CMO effective Sept 1; Sarah Gheuens to assume role.
- Repurchased 10.5M shares for $529M at average price $50.41 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312521228150/0001193125-21-228150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312521228150/d108692d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-228150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer